PROGRAM OVERVIEW

Continuing Education Company has been organizing its Primary Care Conference Series for over 30 years. The **16th Annual Essentials in Primary Care Summer Conference** is designed to update primary care clinicians in rapidly changing therapeutic areas. The emphasis is on practical and useful information for clinical practice. This CME will educate and promote improved patient outcomes in a broad range of therapeutic areas commonly encountered in the primary care practice. It will highlight the latest science related to a variety of specialty areas, presented in a practical and patient-focused manner in the primary care setting. The *16th Annual Essentials in Primary Care Summer Conference* will be held at Hammock Beach Resort in Palm Coast, Florida, July 7 – 11, 2025

LEARNING OBJECTIVES

As a result of this educational activity, participants should be better able to:

- Assess and provide patients with an accurate diagnosis and optimal care for a broad range of disorders seen in primary care.
- Utilize current guidelines in the diagnosis and management of commonly encountered therapeutic issues.
- Formulate comprehensive evidence-based interventions and treatment strategies that will lead to the reduction of risk factors and improved long-term outcomes.

ACCREDITATION

American Academy of Family Physicians: The AAFP has reviewed the 16th Annual Essentials in Primary Care Summer Conference and deemed it acceptable for up to 20.00 live AAFP Prescribed credits. Term of Approval is from 07/07/2025 – 07/11/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



AMA PRA Category 1 Credits™: Continuing Education Company, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Continuing Education Company designates this live activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please allow



completion information to ACCME for the purpose of granting ABIM MOC credit. Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

UNLABELED USE DECLARATION

During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use

STATEMENT OF DISCLOSURE AND INDEPENDENCE

It is the policy of Continuing Education Company (CEC) to ensure all of its accredited educational activities are designed, implemented, and evaluated in accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Criteria and Policies. In accordance with ACCME requirements, CEC has Relevant Financial Relationship Disclosure Policies that are designed to ensure that accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.

All individuals who are in position to influence and/or control content of a CEC accredited Continuing Medical Education (CME) activity must disclose any financial interest or other relationships they have with an ineligible company, which is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Relevant financial interest or other relationship includes such things as grants or research support, employee, consultant, major stockholder, member of speakers' bureau, etc.) The intent of this disclosure is to provide activity participants with information to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusions. All relevant financial relationships have been identified, mitigated, and are listed below.

The opinions, ideas, recommendations, and perspectives expressed in the syllabus and accompanying presentations at this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Continuing Education Company, advisory boards or consultants.

REVIEW AND PLANNING COMMITTEE DISCLOSURES

The following individuals have indicated that they have no financial relationships with an ineligible company that may impact upon this CME activity:

Raymond E. Major, MD - Reviewer

Su Barnwell – Planner (Continuing Education Company)

Walter Ejnes, CHCP – Planner & Reviewer (Continuing Education Company)

Annie Mullins, MBA, CMP, CPCC – Planner (Continuing Education Company)

Lizzie Masters, CHCP – Reviewer (Continuing Education Company)

Beth Ryan Townsend, CHCP – Reviewer (Continuing Education Company)

FACULTY DISCLOSURES

The following individuals were responsible for developing their own content, which has been reviewed by Continuing Education Company's Medical Education Advisory Committee to ensure it is unbiased. Continuing Education Company has ensured that all relevant financial relationships that faculty may have with ineligible companies have been mitigated in advance of the CME activity. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty	Disclosures	Company
Jan Basile, MD	Research Grant	Ablative Solutions (Target BP I)
	Consultant	Alnylam
	Consultant	Blue Earth Diagnostics
	Research Grant	Corcept (MOMENTUM)
	Consultant	Eli Lilly (SURPASS-CVOT)
	Research Grant	Eli Lilly (TRIUMPH)
	Consultant	Idorsia (Hypertension)
	Consultant	Medtronic (Renal Denervation Program)
	Consultant	Mineralys
	Consultant	Novo Nordisk
	Research Grant	ReCor (Radiance I and II)
	Consultant	ReCor (Renal Denervation)
	Consultant	UpToDate (Hypertension Section)
Marc-André Cornier, MD	Data Safety Monitory Board	Advarra
	Research Grant	Amgen
	Consultant	AstraZeneca
	Advisory Board	Biophytis
	Research Grant	Cleerly
	Advisory Board	Eli Lilly
	Research Grant	Ionis Pharmaceuticals
	Research Grant	Kaneka
	Advisory Board	Keros
	Research Grant	Novartis
	Advisory Board	Pfizer Pharmaceuticals
	Advisory Board	Wave
	Advisory Board	Zyversa
Robert Dachs, MD	Nothing to Disclose	
George L. Higgins, III, MD	Nothing to Disclose	
Heather Johnson, MD	Consultant	Amgen
	Consultant, Speaker Bureau	Esperion Therapeutics
	Consultant	Medtronic (Renal Denervation Program)
	Consultant	Novartis

Scott Kaatz, DO	Consultant	Anthos
	Consultant	AstraZeneca
	Consultant	Bayer
	Consultant	Gilead
	Research Grant	Inari
	Consultant	Perosphere
	Consultant, Research Grant	Regeneron
Kevin Pantalone, DO	Speaker's Bureau	AstraZeneca
	Consultant, Research Grant	Bayer
	Consultant	Boehringer Ingelheim
	Consultant, Speaker's Bureau	Corcept Therapeutics
	Consultant	DIASOME
	Consultant, Research Grant	Eli Lilly
	Consultant, Research Grant	Merck
	Consultant, Research Grant, Speaker's Bureau	Novo Nordisk
	Consultant	Sanofi
	Research Grant	Twin Health
John Post, III, MD	Nothing to Disclose	
Kay Roussos-Ross, MD	Nothing to Disclose	
Jennifer Woodward, MD	Nothing to Disclose	